MARKET

TARO

TARO

Taro Pharm
NYSE

Real-time Quotes | Nasdaq Last Sale

71.02
+0.13
+0.18%
Opening 15:23 12/04 EST
OPEN
72.18
PREV CLOSE
70.89
HIGH
72.39
LOW
70.02
VOLUME
14.37K
TURNOVER
--
52 WEEK HIGH
99.69
52 WEEK LOW
53.95
MARKET CAP
2.72B
P/E (TTM)
-10.1256
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Taro Pharmaceutical Industries Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Taro Pharmaceutical Industries Ltd. (NYSE:TARO) will be discussing their earnings results in their 2020 Second Quarter Earnings call to be held on October 29, 2020 at 8:00 AM Eastern Time.
ACCESSWIRE · 10/29 10:01
Taro Provides Results for September 30, 2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and six months ended September 30, 2020.
BusinessWire · 10/28 18:15
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 10/25 18:42
Taro to Announce Second Quarter Results on October 28, 2020
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2020, on Wednesday, October 28, 2020.
BusinessWire · 10/21 22:44
Summers Value Partners Q3 2020 Investor Letter
Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate.The Summers Value Fund LP declined by 1.2% net during the first nine months of 2020, outpacing the Russell 2000 Index return of -9.6% and the Russell Microcap Index return of -9.1%.Our shorting activities continue to be limited as we wait for better opportunities. The Fund has generated a small loss on the short side year-to-date.We currently have more ideas than we do capital. We added two new positions in the third quarter, and our idea funnel remains full.
Seekingalpha · 10/15 19:40
The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4%
, /PRNewswire/ -- The topical drug delivery market is projected to reach by 2025 from in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns. However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period.Read the full report: Based on product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products.The semi-solid formulations segment accounted for the larger market share in 2019.The easy application of semi-solid formulations, and their ability to deliver a wide variety of drug molecules is resulting in a stable demand for this segment among end users.Based on route of administration, the topical drug delivery market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal, vaginal drug delivery, and nasal drug delivery.The dermal drug delivery segment is expected to witness the highest growth during the forecast period.This is mainly due to the advantages of dermal drug delivery over other topical drug delivery methods, such as convenience and greater patient compliance. Besides, dermal products have fewer regulatory requirements than ophthalmic products, where sterility testing is mandatory.The home care settings segment accounted for the largest share of the market in 2019.This is attributed to the factors such as the convenience and affordability of topical drugs for home administration.Also, for patients requiring long-term therapy, inpatient care is not only extremely expensive but also prevents patients from resuming a normal lifestyle and work activities. In this regard, technological advancements have helped patients undergo therapies effectively and safely at home.The topical drug delivery market in the is estimated to grow at the highest CAGR during the forecast period. This is due to high incidence of skin diseases (such as skin cancer), increasing use of contraceptives, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, all of which are driving adoption of topical drug delivery in the .• By Company Type – Tier 1–55%, Tier 2–25% and Tier 3–20%• By Designation – C-level–43%, Director-level–32%, Others–25%• By Region – North America–38%, Europe–29%, Asia Pacific–23%, RoW- 10%The key players operating in the topical drug delivery market include Johnson & Johnson (US), Nestlé SA (), Novartis AG (), GlaxoSmithKline (UK), Bausch Health Companies (), Merck & Co (US), Bayer AG (), Hisamitsu Pharmaceutical (), Glenmark Pharmaceuticals (), Cipla Ltd (), Crescita Therapeutics Inc. (), Mylan (US), Encore Dermatology, Inc. (US), LEO Pharma (), Almirall, S.A (), Aclaris Therapeutics, Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teligent Pharma (US), Perrigo Pharma (US), Allergan (), Biofrontera, Inc. (US), Crown Laboratories Inc. (US), Akorn Inc. (US), Ingenus Pharmaceuticals (US), and Sun Pharmaceuticals ().The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region.The report also includes a product portfolio matrix of various topical drug delivery products available in the market.The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global topical drug delivery market. The report analyzes this market by product, route of administration, and facility of use• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market• Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.Read the full report: About ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare:    US: (339)-368-6001 Intl: +1 339-368-6001
PR Newswire - PRF · 10/07 11:50
Taro Pharmaceutical launches generic Deferiprone in U.S.
Taro Pharmaceutical ([[TARO]] -0.5%) has announced the launch of deferiprone, a generic version of Chiesi's Ferriprox, an iron chelator indicated for transfusional iron overload due to thalassemia syndromes, when current chelation therapy is not sufficient.The company will team up
Seekingalpha · 09/28 18:09
Taro Launches Specialty Generic Deferiprone Tablets, 500mg In The U.S.
Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) ("Taro" or "the Company") today announced the launch of a new specialty generic,
Benzinga · 09/28 17:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARO. Analyze the recent business situations of Taro Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TARO stock price target is 80.00 with a high estimate of 80.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 5.31M
% Owned: 13.89%
Shares Outstanding: 38.26M
TypeInstitutionsShares
Increased
28
273.56K
New
15
-17.88K
Decreased
25
181.70K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.02%
Pharmaceuticals & Medical Research
+1.48%
Key Executives
Chairman/Director
Dilip Shanghvi
Chief Executive Officer/Director
Uday Baldota
Vice Chairman/Director
Abhay Gandhi
Chief Financial Officer/Chief Accounting Officer/Vice President
Daphne Huang
Vice President/General Counsel/Secretary
Erik Zwicker
Vice President/Director of Human Resources
Michele Visosky
Vice President
Richard Glaze
Vice President
Ori Gutwerg
Vice President
Itamar Karsenti
Vice President
Chantal LeBlanc
Vice President - Research & Development
Avi Avramoff
Other
Jayesh Shah
Director
James Kedrowski
Director
Sudhir Valia
Independent Director
Linda Benshoshan
Independent Director
Dov Pekelman
Independent Director
Robert Stein
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
11/05/2018
Dividend USD 0
12/10/2018
11/05/2018
Special Dividend USD 12.81
12/10/2018
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TARO
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Taro Pharmaceutical Industries Ltd. stock information, including NYSE:TARO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARO stock methods without spending real money on the virtual paper trading platform.